M&T Bank Corp Acquires 13,910 Shares of Biogen Inc. $BIIB

M&T Bank Corp grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 94.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 28,565 shares of the biotechnology company’s stock after purchasing an additional 13,910 shares during the quarter. M&T Bank Corp’s holdings in Biogen were worth $5,027,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BIIB. Convergence Investment Partners LLC bought a new position in shares of Biogen in the third quarter worth about $1,342,000. Caprock Group LLC acquired a new stake in shares of Biogen in the third quarter valued at approximately $742,000. Leuthold Group LLC acquired a new stake in shares of Biogen in the third quarter valued at approximately $3,294,000. Generali Investments Management Co LLC raised its position in Biogen by 408.2% in the 3rd quarter. Generali Investments Management Co LLC now owns 9,970 shares of the biotechnology company’s stock worth $1,397,000 after purchasing an additional 8,008 shares during the last quarter. Finally, CWM LLC raised its position in Biogen by 36.4% in the 3rd quarter. CWM LLC now owns 47,455 shares of the biotechnology company’s stock worth $6,648,000 after purchasing an additional 12,673 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Price Performance

Shares of BIIB stock opened at $184.38 on Monday. The firm’s 50 day moving average price is $185.13 and its two-hundred day moving average price is $175.36. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen Inc. has a 52-week low of $115.25 and a 52-week high of $202.41. The stock has a market cap of $27.06 billion, a PE ratio of 20.93, a PEG ratio of 2.46 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. The company had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts forecast that Biogen Inc. will post 15.76 EPS for the current year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.18% of the stock is currently owned by company insiders.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a China deal to develop felzartamab as a domestically produced anti‑CD38 therapy for multiple myeloma — this expands its China footprint and could open a meaningful growth market. Biogen seeks Darzalex rivalry in China for multiple myeloma with felzartamab deal
• Positive Sentiment: UBS upgraded Biogen, and JPMorgan raised its price target to $185 (still a Neutral rating) — these moves provide some analyst validation for the story but stop short of a full buy case. UBS upgrades Biogen (BIIB) JPMorgan raises price target
• Neutral Sentiment: Q1 earnings preview pieces highlight that new products (Skyclarys, Zurzuvae) are driving growth but legacy MS sales face competitive pressure — outcome of Q1 will be a key catalyst and remains uncertain. Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
• Neutral Sentiment: Rothschild & Co Redburn issued EPS estimates and raised its price target to $180 while maintaining a Neutral rating — adds supply of modeled forecasts but not a bullish call. Rothschild & Co Redburn estimates and target
• Negative Sentiment: Short interest rose to ~4.41M shares as of April 15 (+15.4% vs. March 31), representing about 3.0% of float and a short‑interest ratio ~3.1 days — higher shorting can amplify downward pressure around weak news. (Note: an April 24 data point showing zero shares appears to be a reporting anomaly.)
• Negative Sentiment: Wolfe Research trimmed Q1 and Q2 EPS estimates (and trimmed Q2 guidance), signaling risk to near‑term earnings expectations and likely contributing to negative trading sentiment.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on BIIB shares. Canaccord Genuity Group upped their price objective on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Oppenheimer lifted their target price on Biogen from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. Stifel Nicolaus boosted their target price on Biogen from $202.00 to $214.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. HC Wainwright raised their price target on Biogen from $228.00 to $237.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Finally, JPMorgan Chase & Co. raised their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a report on Thursday. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $211.81.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.